Study of vitamin D 3 on improving cancer fatigue in patients with advanced lung cancer undergoing chemotherapy / 中国基层医药

ABSTRACT

Objective:To study the clinical application effect of vitamin D 3 on improving cancer fatigue in patients with advanced lung cancer undergoing chemotherapy, and to explore the mechanism and treatment of cancer fatigue. Methods:From February 2018 to February 2019, 47 patients with advanced lung cancer undergoing chemotherapy admitted in the People's Hospital of Quzhou were selected.The patients were divided into the control group (24 cases) and the observation group(23 cases) by the random number table method.The two groups were given supportive treatment according to the US clinical oncology clinical practice guidelines 2017 guidelines for cancer fatigue, and the observation group was given vitamin D 3 preventive treatment.The remission of cancer fatigue and the changes of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and interleukin 6 (IL-6) in the two groups were compared. Results:The remission rate of cancer fatigue in the observation group was 69.6% (16/23), which was higher than that in the control group [29.2%(7/24)], the difference was statistically significant(χ 2=7.837, P<0.05). After treatment, the levels of CRP, ESR and IL-6 in the observation group were (26.98±7.51)mg/L, (30.50±7.00)mm/h and (7.00±4.08)ng/L, respectively, which were lower than those in the control group [(41.02±6.63)mg/L, (33.25±4.34)mm/h and (10.75±4.57)ng/L], and the differences were statistically significant ( t=9.11, 2.56 and 2.47, all P<0.05). Conclusion:The preventive use of vitamin D 3 in chemotherapy for advanced lung cancer patients can improve cancer fatigue and reduce the level of inflammatory factors.